Brief: AN2 Therapeutics Announces Research Collaboration With GSK
10/11/2025 12:09
Nov 10 (Reuters) - AN2 Therapeutics Inc ANTX.O: AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB) AN2 THERAPEUTICS: GATES FOUNDATION WILL PROVIDE THIRD YEAR OF FUNDING TO SUPPORT AN2'S WORK WITHIN COLLABORATION Source text: ID:nBwb9X3F1a Further company coverage: ANTX.O ((reuters.briefs@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview